Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2001

View Archived Issues

Amgen advances antibody into clinical trials, triggering milestone payment to Abgenix

SangStat enters into collaborations geared toward next-generation RDP-58 molecules

Licensing opportunity from NIH: immunostimulant LL-37

Vibrio cholerae O139 conjugate vaccines available for licensing from NIH

3M seeks additional FDA approval of QVAR

New Photofrin indication filed with Canadian authorities

Positive long-term survival and safety data reported for OvaRex

Idec submits additional information for Zevalin BLA

Macrophage aP2 as a target for therapy of atherosclerosis

Neutrophil elastase inhibitor prevents cancer metastasis in animal model

Direct factor Xa inhibitor DX-9065a shows promise for thrombosis and restenosis

Good safety, dose-proportional pharmacokinetics seen in early clinical trial of rPSGL-Ig

Ceprotin has beneficial therapeutic and prophylactic effects in protein C deficiency

FDA issues approvable letter for Natrecor

Identification, structure and biological activity of new glycoprotein trafficking inhibitor

Exelixis delivers cancer antibody targets to PDL for further development

Rational design of mesangial cell proliferation inhibitors

Microcide and Naeja to codevelop novel antifungal agents

Lexicon/Coelacanth merger complete

Excellent antibacterial profile demonstrated for HMR-3562 against enterococci

Olamufloxacin has high activity in murine models of systemic infections and UTIs

CDK-inhibitory quinazolines particularly useful for proliferative cardiovascular disorders

Cor's new anticoagulants presented in patent literature

Antiinflammatory compounds reported by Boehringer Ingelheim

Nontoxic MMP inhibitor from Pharmacia with antitumor activity

CXC chemokine inhibitors under development by French lab

Potent and selective antagonists of neuropeptide Y5 receptors identified at Shionogi

Enzo Biochem cleared to begin trial of immune regulation medicine for Crohn's disease

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...